Sam Wadsworth, Ph.D.

Sam Wadsworth, Ph.D., has authored over 80 peer-reviewed papers including some of the earliest published work on adeno-associated viral (“AAV”) vectors for gene therapies and owns over a dozen patents related to AAV vectors for gene therapies. Since April 2022, Dr. Wadsworth has served as the Senior Scientific Advisor for Ultragenyx Gene Therapy, an operating unit of Ultragenyx Pharmaceutical Inc. Prior to that, Dr. Wadsworth served as the Chief Scientific Officer of Ultragenyx Gene Therapy since November 2017, with responsibility for discovery and research and development of gene therapy programs following Ultragenyx’s acquisition of Dimension Therapeutics, Inc., where Dr. Wadsworth served as Chief Scientific Officer from 2013 until November 2017. From 2010 to 2013, Dr. Wadsworth served as the Director of Molecular Biology at Genzyme Corporation and, subsequent to the acquisition by Sanofi in 2011, the Global Head of Gene Therapy overseeing discovery and translational research on multiple rare disease and gene therapy programs. Dr. Wadsworth’s academic credentials include a Ph.D. from the University of Chicago and a B.A. from Southern Illinois University.